Skip to content

Our approach to research excellence

The Institute of Cancer Therapeutics is world-renowned for research, training and partnership with industry. Our excellence is testified by substantial investment from industry and research councils, leading to high impact outputs, innovation and knowledge transfer.

The REF2014 assessment (Allied Health) placed 92% of the Institute’s research outputs in the 4* and 3* categories, and 100% of its impact and environment studies in the 4* and 3* categories Research Excellence Framework Assessment 2014

Recent Publications


Peter K Nicholls, David C Page. Germ cell determination and the developmental origins of germ cell tumors (2021) Development 148 doi:10.1242/dev.198150

Barnieh, F.M.; Loadman, P.M.; Falconer, R.A.* “Progress towards a clinically-successful ATR inhibitor for cancer therapy.” Current Research in Pharmacology and Drug Discovery, 2021, 2, 100017.

Guo, X.; Elkashef, S.M.; Patel, A.; Ribeiro Morais, G.; Shnyder S.D.; Loadman, P.M.; Patterson, L.H.; Falconer, R.A.* “An assay for quantitative analysis of polysialic acid expression in cancer cells.” Carbohydrate Polymers, 2021, 259, 117741.

Ribeiro Morais, G.*; Falconer, R.A.* “Glycosyl disulfides: importance, synthesis and application to chemical and biological systems.” Organic and Biomolecular Chemistry, 2021, 19, 82-100.

Ringaile Zaksauskaite, Ruth C Thomas, Freek van Eeden, Sherif F. El-Khamisy; Tdp1 protects from topoisomerase 1–mediated chromosomal breaks in adult zebrafish but is dispensable during larval development; Science Advances,  29 Jan 2021: Vol. 7, no. 5; DOI: 10.1126/sciadv.abc4165


Guo, X.; Malcolm, J.R.; Ali, M.M.; Ribeiro Morais, G.; Shnyder, S.D.; Patterson, L.H.; Loadman, P.M.; Falconer, R.A. An efficient assay for identification and quantitative evaluation of potential polysialyltransferase inhibitors. Analyst, 2020, 145. 4512-4521.

Fielden J, Wiseman K, ……Maughan TS, El-Khamisy SF, Ramadan K (2020). TEX264 coordinates p97- and SPRTN-mediated resolution of topoisomerase 1-DNA adducts. Nature communications, 9;11(1):1274.

Nicola Ingram; Laura E McVeigh; …………Neil H Thomson; Paul M Loadman; …………; P Louise Coletta Targeted, Ultrasound - Triggered Microbubbles Enhance the Therapeutic Range of Cytotoxic Drugs, (2020) Theranostics; 10(24):10973-10992.

Quattrini, L.; Sadiq, M.; Petrarolo, G.; Maitland, N.J.; Frame, F.M.; Pors, K.; La Motta, C. Aldehyde Dehydrogenases and Prostate Cancer: Shedding Light on Isoform Distribution to Reveal Druggable Target. Biomedicines 2020, 8, 569.

Ahmet DS, Basheer HA, Salem A, Lu D, Aghamohammadi A, Weyerhäuser P, Bordiga A, Almeniawi J, Rashid S, Cooper PA, Shnyder SD, Vinader V, Afarinkia K. Application of small molecule FPR1 antagonists in the treatment of cancers. Sci Rep. 2020;10(1):17249.

Synthesis and Characterization of Novel Nopyl-Derived Phosphonium Ionic Liquids J. Yu, R.T. Wheelhouse, M.A. Honey* and N. Karodia*.  J. Mol. Liq. (2020)

Soldevila-Barreda J, Azmanova M, Pitto-Barry A, Cooper P, Shnyder S, Barry N (2020). Preclinical anticancer activity of an electron-deficient organoruthenium (II) complex. ChemMedChem. 15:982-987.

Mikedis MM, Nicholls PK, Fan Y, Endo T, Jackson EK, de Rooij DG, Page DC. DAZL mediates a broad translational program regulating expansion and differentiation of spermatogonial progenitors. eLife. 2020; 9: e56523.


Wu, W.; Klockow, ………...; Loadman, P.M.; Falconer, R.A.; Mukherjee, S.; Chin, F.T.; Daldrup-Link, H. “Radiation plus theranostic combination therapy for targeting glioblastomas.” Nanotheranostics, 2019, 3, 299-310.

Lomba L, Afarinkia K, Vinader V. A new route to tricyclane sesquiterpenoids: total synthesis of α-ekasantalic acid. Org Biomol. Chem. 2019;17(18):4456-4459.

O'Flaherty L, Shnyder SD, Cooper PA, Cross SJ, Wakefield JG, Pardo OE, Seckl MJ, Tavaré JM (2019). Tumor growth suppression using a combination of taxol-based therapy and GSK3 inhibition in non-small cell lung cancer. PLoS One. 14: e0214610.

Jones HS; Papageogiou M; Gordon A; Ehtesham; Javed Z; Wells E; Rigby A; Atkin SL; Courts FL; Sathyapalan T.  Physiologically-relevant screening of polyphenol-rich commercial preparations for bioactivity in vascular endothelial cells, and application to human volunteers: a viable workflow and cautionary tale (2019). – Biochemical Pharmacology, 173, 113754.

Nicholls PK, Schorle H, Naqvi S, Hu YC, Carmell MA, Fan Y, Dobrinski I, Watson AL, Carlson DF, Fahrenkrug SC and Page DC. 2019 Mammalian germ cells are determined after PGC colonization of the nascent gonad. Proceedings of the National Academy of Sciences, USA.116(51):25677-25687.


Walker C, Herranz-Martin S, ……… ShawPJ, Hautbergue GM, Azzouz M, El-Khamisy SF. (2018). C9orf72 Expansion Disrupts ATM-mediated Chromosomal Break Repair. Nature Neuroscience, 45: 1159.

Mark A Hull,……….Paul M Loadman, E. Williams, Diane Whitham, Alan A Montgomery, on behalf of the seAFOod Collaborative Group (2018), Eicosapentaenoic acid (EPA) and/or aspirin for prevention of colorectal adenomas (The seAFOod Polyp Prevention Trial): a multicentre, double-blind, placebo-controlled, randomised 2x2 factorial phase 3 trial. The Lancet, Vol 392 p2583-94.

Henry Watson, …….Jade A Spencer, …….. Paul M Loadman, Mark A Hull, A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota, Gut, (2018);67:1974–1983.

S.J. Allison, D. Cooke, F.S. Davidson, P.I.P. Elliott, R.A. Faulkner, H.B.S. Griffiths, O.J. Harper, O. Hussain, P.J. Owen-Lynch, R.M. Phillips,* C.R. Rice,* S.L. Shepherd and R.T. Wheelhouse. Ruthenium-containing Linear Helicates and Mesocates with Tuneable p53 Selective Cytotoxicity in Colorectal Cancer Cells.  Angew. Chem. Int. Ed. (2018) 130, 9947–9952. 

D. Cousin, …………W. Lewis, R.T. Wheelhouse and M.F.G. Stevens. Synthesis and growth-inhibitory activities of imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamides related to the anti-tumour drug temozolomide, with appended silicon, benzyl and heteromethyl groups at the 3-position. Med Chem Comm (2018) 9, 545–553.


RGD-Binding Integrins in Head and Neck Cancers, H. T. Ahmedah, L H. Patterson, S. D. Shnyder and H. M. Sheldrake. Cancers 2017, 9, 56;

Moody, H. L., Lind, M. J., & Maher, S. G. (2017). MicroRNA-31 Regulates Chemosensitivity in Malignant Pleural Mesothelioma. Molecular therapy. Nucleic acids, 8, 317–329.